EBM BLS: 12 Months of Low-dose Apixaban Decreased Venous Thromboembolism Recurrence After 3 Months of Initial Treatment of a Triggered Venous Thromboembolism with Continuing Risk Factors | Synapse
June 3, 2026
EBM BLS: 12 Months of Low-dose Apixaban Decreased Venous Thromboembolism Recurrence After 3 Months of Initial Treatment of a Triggered Venous Thromboembolism with Continuing Risk Factors
Key Points
The aim is to evaluate the effectiveness of low-dose apixaban in reducing venous thromboembolism recurrence after initial treatment.
Participants given low-dose apixaban for 12 months following 3 months of initial treatment.
Designed as a randomized trial focusing on individuals with continuing risk factors.
Significant decrease in venous thromboembolism recurrence rate after 12 months of treatment.
Statistical analysis indicated a strong positive outcome in the measured population.